ClinicalTrials.gg
RecruitingNCT07627139Updated Nov 2, 2026

Metacognitive Bibliotherapy for Anxiety, Depression, and Metacognitions in University Students

An interventional study of Zihninde Çok Kuran İnsanlar için Salma Rehberi and Çapa Atmak in Anxiety, Depression and Stress (Psychology), sponsored by Istanbul Nisantasi University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Primary conditionDepressionRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depression
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Depression.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Istanbul Nisantasi University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 2, 2026Now RecruitingFirst site in Turkey (Türkiye)+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 343 studies in Depression with a site in Turkey — 59 open to participants now, 71 under way, none of them phase 3. Depression · Turkey.

Planned enrollment
27th of 246
165 · median 60
Started
2026
with 39 others
No phase
239 of 343
43 open now
Primary completion
2027-01
later than 56 of 70 live
Registered
304th of 343
by date

Among the 343 studies in Depression with a site in Turkey, this one is the 27th largest by planned enrollment of the 246 interventional ones that give a count, is one of 40 that started in 2026, is one of 239 with no phase, reaches primary completion later than 56 of the 70 other live ones, and was the 304th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

59 of the 343 studies in Depression with a site in Turkey are open now. Recruiting first, the newest first:

53 more — sign in →

All 59 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 343 studies in Depression with a site in Turkey, or all of them as a file.
02

Study summary

This study tests whether reading a structured self-help book (bibliotherapy) can reduce anxiety, depression and stress and change unhelpful thinking patterns in medical and health-sciences students.

Students in health programs face heavy academic and clinical demands and are at increased risk of emotional distress. A thinking style called the Cognitive Attentional Syndrome (worry, rumination, threat monitoring and unhelpful coping) is thought to link stress to anxiety and depression. Metacognitive therapy targets this thinking style, and low-intensity self-help books may make these principles accessible to students.

A total of 165 students at İstanbul Nişantaşı University will be randomly assigned to one of three groups: two groups each receive a different self-help book and read it at their own pace over 8 weeks, and the third group (waitlist) receives the books after the study ends. All participants complete short online questionnaires (DASS-21, CAS-1, MCQ-30) at the start, at week 4 and at week 8, and receive brief telephone calls at weeks 2, 4 and 6 to confirm participation.

Read the detailed description

Design: Single-site, parallel-group, three-arm randomized controlled trial at İstanbul Nişantaşı University, Istanbul, Türkiye.

Participants: Students aged 18 years or older enrolled in medicine or health-sciences programs (medicine, psychology, nursing and dentistry), recruited through announcements (student WhatsApp groups, e-mail and brief in-class presentations). Participation is voluntary and has no effect on academic standing.

Arms: (1) Bibliotherapy with the self-help book "Zihninde Çok Kuran İnsanlar için Salma Rehberi"; (2) bibliotherapy with the self-help book "Çapa Atmak"; (3) waitlist control, assessment only during the study period, with books provided at the end of the study. Reading is self-paced over 8 weeks without therapist contact.

Randomization: After completion of baseline assessments, participants are allocated 1:1:1 using a computer-generated random sequence (Randomizer.org). Faculty and baseline DASS-21 total score are taken into account to support balance between groups; the DASS-21 score is not used as an inclusion threshold. The allocation list is stored securely by the research team, and allocation is not disclosed until baseline assessments are complete.

Sample size: G*Power 3.1, medium effect size (f = 0.25), three groups, α = 0.05, power 80%: minimum 159 participants. 165 participants (55 per arm) are targeted.

Measures and schedule: Sociodemographic form at baseline. Depression Anxiety Stress Scales-21 (DASS-21), Cognitive Attentional Syndrome Scale-1 (CAS-1) and Metacognitions Questionnaire-30 (MCQ-30) at week 0, week 4 and week 8, collected online through a study website after electronic informed consent. Process measures: a weekly one-item reading log in the two bibliotherapy arms, and a three-item contamination form at week 8.

Telephone contact: All participants, including the waitlist group, receive brief standardized telephone calls at weeks 2, 4 and 6 to confirm participation, reading progress and completion of forms. Calls follow a fixed script, serve reminder and confirmation purposes only, and contain no therapeutic content or guidance about the books, so that contact intensity is equal across arms.

Safety: Participants with current psychiatric treatment, a recent change in psychotropic medication, bipolar disorder, acute psychotic symptoms or suicide risk are not included. If questionnaire responses indicate a high level of distress during the study, the research team contacts the participant and refers them to appropriate mental health services.

Analysis: Repeated-measures ANOVA (or non-parametric alternatives) to examine group × time effects, with baseline scores taken into account; partial eta-squared is reported as the effect size; intention-to-treat principles are applied for missing data. SPSS is used.

Data protection: Participants are identified only by study codes. Telephone numbers are collected with consent for study contact only and stored separately from the dataset. Data are stored under encryption in accordance with Turkish personal data protection law (KVKK), and no personal identifiers appear in reports or publications.

03

Conditions studied

  • Anxiety
  • Depression
  • Stress (Psychology)

Browse trials for

Keywords

  • Metacognition
  • Psychological Distress
  • self-help
  • rumination
  • worry
04

In context

Depression Reclassified

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

This study's planned enrollment of 165 is above the median of 81 across 7,089 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Istanbul Nisantasi University is the lead sponsor of 22 studies on the registry; 8 are open to participants now.

Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Nov 2, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Currently enrolled as a student in a medicine or health-sciences program (medicine, psychology, nursing and dentistry) at İstanbul Nişantaşı University
  • Sufficient proficiency in reading and understanding Turkish
  • Access to an internet-connected device to complete online forms
  • Electronic

Exclusion criteria

Exclusion Criteria:

  • Currently receiving active psychiatric treatment (psychotherapy or psychotropic medication)
  • Change in psychotropic medication within the last 6 months
  • Having previously read either of the study books
  • Diagnosis of bipolar disorder
  • Acute psychotic symptoms or current suicide risk
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
165 participants (estimated)

Study arms

  • Experimental
    Bibliotherapy - Group 1

    Participants receive the self-help book "Zihninde Çok Kuran İnsanlar için Salma Rehberi" at study start and read it at their own pace over 8 weeks. They complete online questionnaires at weeks 0, 4 and 8, a weekly one-item reading log, and receive brief telephone calls at weeks 2, 4 and 6.

    Behavioral: Zihninde Çok Kuran İnsanlar için Salma Rehberi

  • No intervention
    Waiting List Control

    Participants complete the same online questionnaires at weeks 0, 4 and 8 and receive the same brief telephone calls at weeks 2, 4 and 6. The study books are provided after the 8-week study period.

  • Experimental
    Bibliotherapy - Group 2

    Participants receive the self-help book "Çapa Atmak" at study start and read it at their own pace over 8 weeks. They complete online questionnaires at weeks 0, 4 and 8, a weekly one-item reading log, and receive brief telephone calls at weeks 2, 4 and 6.

    Behavioral: Çapa Atmak

Interventions

  • BehavioralZihninde Çok Kuran İnsanlar için Salma Rehberi

    Structured self-help book based on metacognitive therapy principles, targeting the Cognitive Attentional Syndrome (worry, rumination, threat monitoring and unhelpful coping strategies). Participants read the book at their own pace over 8 weeks without therapist contact. Reading progress is recorded with a weekly one-item online reading log.

  • BehavioralÇapa Atmak

    Self-help book read under the same conditions as Intervention 1: self-paced reading over 8 weeks without therapist contact, with a weekly one-item online reading log.

07

What researchers measure

Primary outcomes

  1. Change in Depression, Anxiety, and Stress Scales (DASS-21) total score

    DASS-21 (Turkish version), 21 items rated 0-3; total score is the sum of all items (range 0-63). Higher scores indicate greater psychological distress. Change from baseline to week 8 is compared between groups.

    Time frame: Baseline (week 0) to week 8

Secondary outcomes

  1. Change in Cognitive Attentional Syndrome Scale-1 (CAS-1) score

    CAS-1 (Turkish version), 16 items. Items 1-10 (worry/rumination, threat monitoring and unhelpful coping behaviours) are rated on a 0-8 scale; items 11-16 (metacognitive beliefs) are rated on a 0-100 scale. Higher scores indicate greater Cognitive Attentional Syndrome activity.

    Time frame: Baseline (week 0), week 4 and week 8

  2. Change in Metacognitions Questionnaire-30 (MCQ-30) total score

    MCQ-30 (Turkish version), 30 items rated 1-4 (range 30-120). Higher scores indicate more maladaptive metacognitive beliefs.

    Time frame: Baseline (week 0), week 4 and week 8

  3. Change in DASS-21 Anxiety subscale score

    7 items of the DASS-21 anxiety subscale, rated 0-3 (range 0-21). Higher scores indicate more anxiety symptoms.

    Time frame: Baseline (week 0), week 4 and week 8

Other outcomes

  1. Reading adherence

    Weekly one-item online reading log in the two bibliotherapy arms, recording the section of the book reached; summarized as the proportion of the book completed.

    Time frame: Weekly, weeks 1-8

  2. Contamination between study groups

    Three-item form assessing access to the other group's book, sharing of book content between participants, and use of other psychological support during the study.

    Time frame: Week 8

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared outside the research team. This is in line with the ethics committee approval and the informed consent form, which state that data will be used only by the research team for the purposes of this study. Aggregate results will be published in a peer-reviewed journal.

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jan 2027, 2 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 2 months is below that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Jun 2026 → Oct 2026, primary completion Sep 2026 → Jan 2027 and completion Oct 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2026
First posted
Jun 4, 2026
StartActual
Oct 19, 2026was Jun 2026
Primary completionEst.
Jan 4, 2027was Sep 2026
CompletionEst.
Jan 15, 2027was Oct 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 2, 2026
Sites
1 site added — first site in Turkey (Türkiye)
Show site
  • Istanbul Nişantaşı University · Istanbul, Turkey (Türkiye)
Nov 2, 2026
Start date
Jun 15, 2026→Oct 19, 2026 (actual)
Nov 2, 2026
Primary completion
Sep 30, 2026→Jan 4, 2027
Nov 2, 2026
Study completion
Oct 31, 2026→Jan 15, 2027
Nov 2, 2026
Enrollment
110→165
Nov 2, 2026
Eligibility
Maximum age 25 Years→none; 5 inclusion criteria added, 3 removed; 4 exclusion criteria edited, 1 added
What changed in the criteria
Inclusion criteria
  • RemovedActive enrollment in the Faculties of Medicine, Nursing, Pharmacy, Dentistry, or Psychology at Istanbul Nisantasi University
  • RemovedAged between 18 and 25 years
  • RemovedProvision of voluntary digital informed consent
  • AddedAge 18 years or older
  • AddedCurrently enrolled as a student in a medicine or health-sciences program (medicine, psychology, nursing and dentistry) at İstanbul Nişantaşı University
  • AddedSufficient proficiency in reading and understanding Turkish
  • AddedAccess to an internet-connected device to complete online forms
  • AddedElectronic informed consent
Exclusion criteria
  • EditedCurrently receiving active psychiatric treatment (psychotherapy or pharmacotherapypsychotropic medication)
  • EditedChange in psychopharmacologicalpsychotropic medication within the pastlast 6 months
  • EditedPrior reading ofHaving previously read either of the study books
  • AddedDiagnosis of bipolar disorder
  • EditedPresence of acuteAcute psychotic symptoms or suicidalcurrent suicide risk
Nov 2, 2026
Interventions
Added Behavioral: Zihninde Çok Kuran İnsanlar için Salma Rehberi·Behavioral: Çapa Atmak; removed Behavioral: The Art of Letting Go - How to Stop Rumination | Book 1·Behavioral: Anchored | Book 2
Nov 2, 2026
Primary outcomes
1 edited, 1 removed
What changed in the outcomes
  • EditedChange in Depression, Anxiety, and Stress SymptomsScales (DASS-21) total scoreTime frame: Baseline (Week 0), mid-intervention (Week 4), and post-intervention (Week 8) → Baseline (week 0) to week 8
  • RemovedChange in Metacognitive Beliefs (MCQ-30)Time frame: Baseline (Week 0), mid-intervention (Week 4), and post-intervention (Week 8)
Nov 2, 2026
Secondary outcomes
1 edited, 4 added
What changed in the outcomes
  • EditedChange in Cognitive Attentional Syndrome Scale-1 (CAS-1) scoreTime frame: Baseline (Week 0), mid-intervention (Week 4), and post-intervention (Week 8) → Baseline (week 0), week 4 and week 8
  • AddedChange in Metacognitions Questionnaire-30 (MCQ-30) total scoreTime frame: Baseline (week 0), week 4 and week 8
  • AddedChange in DASS-21 Anxiety subscale scoreTime frame: Baseline (week 0), week 4 and week 8
  • Addedother outcomeReading adherenceTime frame: Weekly, weeks 1-8
  • Addedother outcomeContamination between study groupsTime frame: Week 8
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Turkey (Türkiye)
    Show site
    • Istanbul Nişantaşı University · Istanbul, Turkey (Türkiye)
    Start date Jun 15, 2026→Oct 19, 2026 (now actual)
    Primary completion Sep 30, 2026→Jan 4, 2027
    Study completion Oct 31, 2026→Jan 15, 2027
    Enrollment 110→165
    Eligibility Maximum age 25 Years→none; 5 inclusion criteria added, 3 removed; 4 exclusion criteria edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • RemovedActive enrollment in the Faculties of Medicine, Nursing, Pharmacy, Dentistry, or Psychology at Istanbul Nisantasi University
    • RemovedAged between 18 and 25 years
    • RemovedProvision of voluntary digital informed consent
    • AddedAge 18 years or older
    • AddedCurrently enrolled as a student in a medicine or health-sciences program (medicine, psychology, nursing and dentistry) at İstanbul Nişantaşı University
    • AddedSufficient proficiency in reading and understanding Turkish
    • AddedAccess to an internet-connected device to complete online forms
    • AddedElectronic informed consent
    Exclusion criteria
    • EditedCurrently receiving active psychiatric treatment (psychotherapy or pharmacotherapypsychotropic medication)
    • EditedChange in psychopharmacologicalpsychotropic medication within the pastlast 6 months
    • EditedPrior reading ofHaving previously read either of the study books
    • AddedDiagnosis of bipolar disorder
    • EditedPresence of acuteAcute psychotic symptoms or suicidalcurrent suicide risk
    Primary outcomes 1 edited, 1 removed
    What changed in the outcomes
    • EditedChange in Depression, Anxiety, and Stress SymptomsScales (DASS-21) total scoreTime frame: Baseline (Week 0), mid-intervention (Week 4), and post-intervention (Week 8) → Baseline (week 0) to week 8
    • RemovedChange in Metacognitive Beliefs (MCQ-30)Time frame: Baseline (Week 0), mid-intervention (Week 4), and post-intervention (Week 8)
    Secondary outcomes 1 edited, 4 added
    What changed in the outcomes
    • EditedChange in Cognitive Attentional Syndrome Scale-1 (CAS-1) scoreTime frame: Baseline (Week 0), mid-intervention (Week 4), and post-intervention (Week 8) → Baseline (week 0), week 4 and week 8
    • AddedChange in Metacognitions Questionnaire-30 (MCQ-30) total scoreTime frame: Baseline (week 0), week 4 and week 8
    • AddedChange in DASS-21 Anxiety subscale scoreTime frame: Baseline (week 0), week 4 and week 8
    • Addedother outcomeReading adherenceTime frame: Weekly, weeks 1-8
    • Addedother outcomeContamination between study groupsTime frame: Week 8
    Interventions Added Behavioral: Zihninde Çok Kuran İnsanlar için Salma Rehberi·Behavioral: Çapa Atmak; removed Behavioral: The Art of Letting Go - How to Stop Rumination | Book 1·Behavioral: Anchored | Book 2
    + 6 other changes: identifiers, verification date, description, conditions, design details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07627139
Lead sponsor
Istanbul Nisantasi University
Responsible party
Alişan Burak Yaşar (Associate Professor, Istanbul Nisantasi University) — Principal investigator
First posted
Jun 4, 2026
Start date
Oct 19, 2026
Primary completion
Jan 4, 2027 (estimated)
Completion
Jan 15, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Alişan Burak Yaşar, MD, Assoc. Prof.
Contact
alisanburak.yasar@nisantasi.edu.tr
+90 532 424 30 58

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion